Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 1;114(5):817-822.
doi: 10.36660/abc.20200273.

The Effect of Coronavirus Disease 2019 on Cardiovascular Diseases

[Article in English, Portuguese]
Lutfu Askin  1 , Okan Tanrıverdi  1 , Husna Sengul Askin  2
Affiliations
Review

The Effect of Coronavirus Disease 2019 on Cardiovascular Diseases

[Article in English, Portuguese]
Lutfu Askin et al. Arq Bras Cardiol. .

Abstract
in English, Portuguese

Coronavirus disease 2019 (COVID-19) is a global pandemic affecting the world, seen in more than 1,300,000 patients. COVID-19 acts through the angiotensin-converting enzyme 2 (ACE2) receptor. Cardiovascular comorbidities are more common with COVID-19, and nearly 10% of cases develop myocarditis (22% of critical patients). Further research is needed to continue or discontinue ACE inhibitors and angiotensin receptor blockers, which are essential in hypertension and heart failure in COVID-19. Intensive research is promising for the treatment and prevention of COVID-19.

A doença de coronavírus 2019 (COVID-19) é uma pandemia global afetando o mundo, estando presente em mais de 1.300.000 pacientes. O COVID-19 age pelo receptor da enzima conversora de angiotensina 2 (ECA2). As comorbidades cardiovasculares são mais frequentes com COVID-19, e cerca 10% de casos desenvolvem miocardite (22% de pacientes críticas). Mais pesquisas serão necessárias para continuar ou descontinuar inibidores de ECA e bloqueadores dos receptores da angiotensina, que são essenciais para hipertensão e insuficiência cardíaca em COVID-19. Pesquisa intensiva é promissora para o tratamento e a prevenção da COVID-19.

PubMed Disclaimer

Conflict of interest statement

Potencial conflito de interesses

Declaro não haver conflito de interesses pertinentes.

Figures

Figura 1
Figura 1. – Interação dos receptores de SARS-CoV-2. ECA2: enzima conversora de angiotensina 2; TMPRSS2: protease transmembranar, serina 2
Figura 2
Figura 2. – Taxas de comorbidades em pacientes com óbito por COVID-19 na China.
Figure 1
Figure 1. – SARS-CoV-2 receptor interaction.
Figure 2
Figure 2. – Comorbidity rates in patients who died from COVID-19 in China.
See this image and copyright information in PMC

References

    1. 1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020 Feb 19. [Epub ahead of print] - PMC - PubMed
    1. 2. Chan JW, Ng CK, Chan YH, Mok TYW, Lee S, Chu SY, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax. 2003;58(8):686-9. - PMC - PubMed
    1. 3. Badawi A, Ryoo SG. Prevalence of comorbidades in the Middle East respiratory syndrome coronavírus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis. 2016 Aug;49:129-33. - PMC - PubMed
    1. 4. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450-2. - PMC - PubMed
    1. 5. Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Curr Biol. 2020;30(8):1578. - PMC - PubMed

MeSH terms